CMS has proposed delaying the effective date of a rule that would allow multiple best prices in value-based drug purchasing arrangements. | Shutterstock

CMS Moves to Delay Multiple-Best-Price Rule For Value-Based Drug Purchases

The U.S. Centers for Medicare & Medicaid Services (CMS) has proposed to delay implementing a portion of a regulation encouraging value-based purchasing for drugs in the Medicaid program that may lead to drugs having multiple best prices.

Finalized during the final days of the Trump administration, the regulation drew criticism from 340B drug discount program proponents. They said not enough attention was paid to how 340B could be affected by the regulation’s changes to the Medicaid drug rebate program (MDRP).

The U.S. Centers for Medicare & Medicaid Services (CMS) has proposed to delay implementing a portion of a regulation encouraging value-based purchasing for drugs in the Medicaid program that may lead to drugs having multiple best prices.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Attend Our Upcoming Webinar

×


Learn More

Sign up for our free news summaries and alerts